Ospedale Luigi Sacco is a hospital in the quartiere of Vialba in Milan, Italy. It was previously known as "sanatorio di Vialba". It is named for Luigi Sacco, an Italian physician who pioneered smallpox research and vaccination in Italy.

During the past decade, Ospedale Luigi Sacco conducted 95 clinical trials. In the 10-year time frame, 95 clinical trials started and 38 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 48 clinical trials started and 25 clinical trials were completed. i.e. 52.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale Luigi Sacco" #1 sponsor was "ASST Fatebenefratelli Sacco" with 11 trials, followed by "Gilead Sciences" with 11 trials sponsored, "University of Milan" with 9 trials sponsored, "Shire" with 6 trials sponsored and "Bristol-Myers Squibb" with 6 trials sponsored. Other sponsors include 104 different institutions and companies that sponsored additional 76 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale Luigi Sacco" #1 collaborator was "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente" with 2 trials as a collaborator, "Gruppo Oncologico Italiano di Ricerca Clinica" with 2 trials as a collaborator, "Regione Lombardia" with 2 trials as a collaborator and "ALK-Abelló A/S" with 1 trials as a collaborator. Other collaborators include 39 different institutions and companies that were collaborators in the rest 49 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale Luigi Sacco" are "HIV Infections" (9 trials), "Covid19" (7 trials), "Crohn Disease" (5 trials), "Crohn's Disease" (5 trials) and "HIV-1 Infection" (5 trials). Many other conditions were trialed in "Ospedale Luigi Sacco" in a lesser frequency.

Most popular intervention types in "Ospedale Luigi Sacco" are "Drug" (100 trials), "Other" (21 trials), "Procedure" (14 trials), "Device" (8 trials) and "Biological" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "cisplatin" (5 trials), "Etrolizumab" (4 trials), "E/C/F/TAF" (3 trials) and "FTC/TDF" (3 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale Luigi Sacco" are 141 trials for "All" genders, 5 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 46 active trials in "Ospedale Luigi Sacco". 4 are not yet recruiting, 20 are recruiting, 20 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 83 completed trials in Ospedale Luigi Sacco, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale Luigi Sacco, 2 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 80 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 12 trials that are defined as “Not Applicable".

Ospedale Luigi Sacco has several departments that took part in Clinical trials: "I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario "Luigi Sacco"" - 2 trials, "Ospedale L. Sacco, Divisione Di Cardiologia" - 2 trials, "Azienda Ospedaliera Luigi Sacco 1° Divisione Malattie Infettive" - 2 trials, "Pediatria dell' Ospedale Sacco" - 2 trials, "ASST FATEBENEFRATELLI SACCO; Reumatologia (Sacco)" - 2 trials, "Ospedale Fatebenefratelli e Oftalmico - Cardiologia e UCC" - 2 trials